CNTBHealthcare · BiotechnologyThe 8 Wall Street analysts covering Connect Biopharma Holdings Ltd. hold a median 12-month price target of $5.5 — +585.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Connect Biopharma Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (80): Smaller than most of the companies we track.
Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CNTB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +585.6% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 12 Oct 2026 | Leerink Partners | Assumes | Outperform | $4.00 |
| 8 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 2 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 2 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Sept 2026 | BTIG | Maintains | Buy | $10 → $5.00 |
| 30 Sept 2026 | BTIG | Maintains | Buy | — |
| 22 Sept 2026 | Oppenheimer | Maintains | Outperform | — |
| 22 Sept 2026 | Oppenheimer | Maintains | Outperform | $8.00 → $5.00 |
| 17 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 16 Sept 2026 | Canaccord Genuity | Maintains | Buy | — |
| 16 Sept 2026 | Canaccord Genuity | Maintains | Buy | $7.00 → $6.00 |
| 15 Sept 2026 | BTIG | Reiterates | Buy | — |
| 15 Sept 2026 | BTIG | Reiterates | Buy | $10 |
| 9 July 2026 | Oppenheimer | Initiates | Outperform | — |
| 9 July 2026 | Oppenheimer | Initiates | Outperform | $8.00 |
| 26 June 2026 | Piper Sandler | Initiates | Overweight | — |
| 25 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CNTB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Connect Biopharma Holdings Ltd. returned −48.2% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 9% of US stocks
Cheaper than 45% of US stocks
Cheaper than 65% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 7% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Connect Biopharma Holdings Ltd. has a market value of $50.5M and an enterprise value of $21.7M.
Revenue in the twelve months to 30 June 2026: $3.0M. The latest quarter grew 5666.7% year on year.
Net income over the same four quarters: −$69.0M, a −2336.3% net margin.
Diluted earnings per share, trailing twelve months: $−1.19.
Free cash flow in the twelve months to 30 June 2026: −$60.6M.
Trailing P/E: −0.8×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Connect Biopharma Holdings Ltd. employs 64 people — $46K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Connect Biopharma Holdings Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Connect Biopharma Holdings discussed rademikibart and results from the SEABREEZE trial in acute COPD in a transcript.
Why it matters — The transcript concerns a company treatment candidate and trial results relevant to CNTB watchers.
Zacks says CNTB has fallen 25.4% in four weeks and is technically oversold. It notes that analyst agreement on higher earnings estimates could contribute to a trend reversal.
Why it matters — CNTB watchers may note the article's view that selling pressure could be easing alongside raised earnings estimates.
Zacks Investment Research reports that CNTB formed a hammer chart pattern after recently losing value, alongside an upward trend in earnings estimate revisions. The excerpt says this combination could indicate a near-term trend reversal.
Why it matters — CNTB watchers may note the reported chart pattern and earnings-estimate revisions as potential signs of a change in the stock’s recent trend.
Connect Biopharma reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients with acute COPD exacerbations. The study met its primary objective, showing an 81% reduction in treatment failures during the month after an exacerbation.
Why it matters — This positive Phase II result for rademikibart advances a key pipeline candidate in Connect Biopharma's COPD development program.
Connect Biopharma Holdings Limited (NASDAQ:CNTB) reported positive topline results from its global Phase 2 study, with its new COPD therapy showing a significant drop in treatment failure. The results were announced recently by the company.
Why it matters — The positive Phase 2 topline results signal promising clinical progress for Connect Biopharma's new COPD therapy, which could be meaningful for the company's development pipeline.
The 8 Wall Street analysts covering Connect Biopharma Holdings Ltd. have a median 12-month price target of $5.5, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Connect Biopharma Holdings Ltd., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Connect Biopharma Holdings Ltd. 43 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Connect Biopharma Holdings Ltd. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +585.6% from the last close, and Ticker Nerd's factor model ranks Connect Biopharma Holdings Ltd. 43 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Connect Biopharma Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.
Connect Biopharma Holdings Ltd. returned -48.2% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease.
The most recent item we track (Seeking Alpha, 23 Oct 2026): "Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript". Connect Biopharma Holdings discussed rademikibart and results from the SEABREEZE trial in acute COPD in a transcript.
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease. Its current pipeline is built around rademikibart, a monoclonal antibody aimed at interleukin-4 receptor alpha, as well as other research efforts in T cell-driven inflammatory disorders. Connect Biopharma works across respiratory and broader inflammation-related markets, reflecting a focus on diseases where immune signaling plays a central role. Headquartered in San Diego, California, Connect Biopharma Holdings Limited is positioned as a specialist developer of novel biologic treatments within the biotechnology sector.
CEO Dr. Barry David Quart Pharm.D. · 64 employees · United States · https://www.connectbiopharm.com
